Abstract
No public abstract is available from the verified source records.
Open public full textRights: ALLOWED · cc-by · Source: journal-auto-sync:external:CROSSREF_ISSN
Arsalan Rahmani Ghohrodi, Zeinab Savari, Ehsan Talebi, Iman Ahamdi, Abbas Rahdar, Sadanand Pandey
Abstract
Rights: ALLOWED · cc-by · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries (vol 68, pg 394, 2018)
2020
Nanoscale metallic‐organic frameworks as an advanced tool for medical applications: Challenges and recent progress
10.1002/aoc.6982 · 2023
Adherence to oral 6-mercaptopurine in African American and Asian children with acute lymphoblastic leukemia: a Children's Oncology Group study
10.1182/blood-2014-01-552166 · 2014
Treatment of childhood acute lymphoblastic leukaemia: present issues and future prospects
10.1016/0268-960x(92)90015-i · 1992
Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: pro
10.1097/00054725-200502000-00014 · 2005
Adult primary care after childhood acute lymphoblastic leukemia
10.1056/nejmcp1103645 · 2011
Recent advances in nanomaterials for colorimetric cancer detection
10.1039/d0tb02163f · 2021
Nanocarriers as an emerging platform for cancer therapy
10.1201/9780429399039-2 · 2020
Influence of different generations of poly (propylene imine) dendrimers on human erythrocytes
2010
Cisplatin-loaded nanoformulations for cancer therapy: A comprehensive review
10.1016/j.jddst.2022.103928 · 2022
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
Novel epirubicin-loaded nanoformulations: advancements in polymeric nanocarriers for efficient targeted cellular and subcellular anticancer drug delivery
10.1016/j.inoche.2023.110999 · 2023
Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson's disease
10.1016/j.nano.2018.08.004 · 2018
Advances in thiopurine drug delivery: the current state-of-the-art
2021
Revolutionizing anticancer drug delivery: Exploring the potential of tamoxifen-loaded nanoformulations
10.1016/j.jddst.2023.104642 · 2023
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
10.1039/c8cs00896e · 2019
The use of lipid-based nanocarriers for targeted pain therapies
10.3389/fphar.2013.00143 · 2013
Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance
10.3389/fmolb.2020.00193 · 2020
Nanoscaled red blood cells facilitate breast cancer treatment by combining photothermal/photodynamic therapy and chemotherapy
10.1016/j.biomaterials.2017.11.002 · 2018
Innovative nanomaterials for cancer diagnosis, imaging, and therapy: drug deliveryapplications
10.1016/j.jddst.2023.104357 · 2023
Designing dendrimers for biological applications
10.1038/nbt1171 · 2005
Poly (amidoamine) dendrimer-erythromycin conjugates for drug delivery to macrophages involved in periprosthetic inflammation
10.1016/j.nano.2010.10.008 · 2011
The development, characterization and in vivo anti-ovarian cancer activity of poly (propylene imine)(PPI)-antibody conjugates containing encapsulated paclitaxel
10.1016/j.nano.2014.09.006 · 2015
Polyacrylic acid mediated targeted drug delivery nano-systems: a review
10.1016/j.jddst.2023.104169 · 2023
Nanoparticles: properties, applications and toxicities
10.1016/j.arabjc.2017.05.011 · 2019
Nanoparticles for colorectal cancer targeted drug delivery and MR imaging: current situation and perspectives
10.2174/1568009616666151130214442 · 2016
cRGD conjugated mPEG-PLGA-PLL nanoparticles for SGC-7901 gastric cancer cells-targeted delivery of fluorouracil
10.1166/jnn.2012.6213 · 2012
Quantum-dot-based theranostic micelles conjugated with an anti-EGFR nanobody for triple-negative breast cancer therapy
10.1021/acsami.7b05654 · 2017
10.1002/pon.3123
10.1002/pon.3123
MERCER, RD-Temporary remission in Acute Leukemia in Children produced by folic antagonist 4-aminopteroyl-glutamic acid (aminopterin)
10.1056/nejm194806032382301 · 1948
Adsorption/desorption behaviors and SERS chemical enhancement of 6-mercaptopurine on a nanostructured gold surface: The Au20 cluster model
10.3390/molecules26175422 · 2021
Inflammatory bowel disease and corticosteroids: the first RCT
10.1038/s41575-021-00524-3 · 2021
Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases
10.1182/blood.v8.11.965.965 · 1953
Joe Burchenal and the birth of combination chemotherapy
10.1111/j.1365-2141.2006.06072.x · 2006
The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia
10.1182/blood.v26.5.642.642 · 1965
Acute lymphoblastic leukaemia relapsing as acute myelomonocytic leukaemia after a remission of 7 years
10.1111/j.1365-2141.1980.00495.x · 1980
Adherence to oral chemotherapy in acute lymphoblastic leukemia during maintenance therapy in children, adolescents, and young adults: a systematic review
10.3390/curroncol30010056 · 2023
Nanoscale drug delivery systems for cancer therapy using paclitaxel—a review of challenges and latest progressions
10.1016/j.jddst.2023.104494 · 2023
Folate receptor-targeted and GSH-responsive carboxymethyl chitosan nanoparticles containing covalently entrapped 6-mercaptopurine for enhanced intracellular drug delivery in leukemia
10.3390/md16110439 · 2018
Designing chitosan nanoparticles embedded into graphene oxide as a drug delivery system
10.1007/s00289-020-03506-8 · 2022
Investigating the structure of the product of graphene oxide reaction with folic acid and chitosan: density functional theory calculations
10.1080/07391102.2021.2001372 · 2022
Combination therapeutics in complex diseases
10.1111/jcmm.12930 · doi-reference
Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine
10.1016/j.gpb.2016.03.008 · doi-reference
Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities
10.2217/nnm-2018-0120 · doi-reference
Nanocarriers for methotrexate delivery/codelivery in the frame of cancer diagnostics and treatment: a review
10.3389/fbiom.2023.1200670 · doi-reference
Advances in chitosan-based nanoparticles for drug delivery
10.3390/ijms22179652 · doi-reference
Receptor-targeted nanocarriers for therapeutic delivery to cancer
10.3109/09687688.2010.521200 · doi-reference
Nanoparticles as drug delivery systems: a review of the implication of nanoparticles’ physicochemical properties on responses in biological systems
10.3390/polym15071596 · doi-reference
Nanocarrier-based systems for targeted and site specific therapeutic delivery
10.1016/j.addr.2019.07.010 · doi-reference
Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy
10.1111/j.1365-2125.2010.03867.x · doi-reference
Prodrugs for improved drug delivery: lessons learned from recently developed and marketed products
10.3390/pharmaceutics12111031 · doi-reference
Advances in lipid‐based codelivery systems for cancer and inflammatory diseases
10.1002/adhm.202202400 · doi-reference
Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia
10.1007/s00280-020-04097-x · doi-reference
Targeting tumor microenvironment for cancer therapy
10.3390/ijms20040840 · doi-reference
Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy
10.1080/10717544.2017.1410256 · doi-reference
Engineered nanoparticles against MDR in cancer: the state of the art and its prospective
10.2174/1381612822666160617112111 · doi-reference
Drug delivery to resistant tumors: the potential of poly (alkyl cyanoacrylate) nanoparticles
10.1016/j.jconrel.2003.08.005 · doi-reference
6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease
10.1097/00042737-200012110-00010 · doi-reference
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
10.1182/blood-2003-12-4428 · doi-reference
Smart co-delivery of 6-mercaptopurine and methotrexate using disulphide-based PEGylated-nanogels for effective treatment of breast cancer
10.1039/c9nj02470k · doi-reference
Use of allopurinol to mitigate 6-mercaptopurine associated gastrointestinal toxicity in acute lymphoblastic leukemia
10.3389/fonc.2020.01129 · doi-reference
Recent advances in nanoparticle-based co-delivery systems for cancer therapy
10.3390/nano12152672 · doi-reference
Effect of the BH3 mimetic polyphenol (–)-gossypol (AT-101) on the in vitro and in vivo growth of malignant mesothelioma
10.3389/fphar.2018.01269 · doi-reference
Patient counseling about herbal-drug interactions
10.4314/ajtcam.v8i5s.8 · doi-reference
Use of thiopurines in inflammatory bowel disease: an update
10.5217/ir.2020.00155 · doi-reference
Nanocarriers for spleen targeting: anatomo-physiological considerations, formulation strategies and therapeutic potential
10.1007/s13346-016-0304-0 · doi-reference
Understanding and targeting resistance mechanisms in cancer
10.1002/mco2.265 · doi-reference
Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?
10.1124/dmd.113.056176 · doi-reference
Inhibit or evade multidrug resistance P-glycoprotein in cancer treatment: Miniperspective
10.1021/acs.jmedchem.7b01457 · doi-reference
Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases
10.1111/j.1742-4658.2011.08235.x · doi-reference
Population pharmacokinetics of voriconazole in patients with invasive aspergillosis: serum albumin level as a novel marker for clearance and dosage optimization
10.1097/ftd.0000000000000799 · doi-reference
Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 h
10.7326/0003-4819-126-8-199704150-00005 · doi-reference
Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease
10.3748/wjg.v17.i37.4166 · doi-reference
LC–MS/MS method for measurement of thiopurine nucleotides (TN) in erythrocytes and association of TN concentrations with TPMT enzyme activity
10.3389/fphar.2022.836812 · doi-reference
Improved HPLC quantification of 6-mercaptopurine metabolites in red blood cells: monitoring data and literature analysis
10.3390/ijms231911885 · doi-reference
Therapeutic drug monitoring for current and investigational inflammatory bowel disease treatments
10.1097/mcg.0000000000001396 · doi-reference
Development and validation of LC–MS/MS assay for the simultaneous determination of methotrexate, 6-mercaptopurine and its active metabolite 6-thioguanine in plasma of children with acute lymphoblastic leukemia: Correlation with genetic polymorphism
10.1016/j.jchromb.2016.10.035 · doi-reference
Therapeutic drug monitoring of antimetabolic cytotoxic drugs
10.1046/j.1365-2125.1999.00884.x · doi-reference
Development of bio-based fine chemical production through synthetic bioengineering
10.1186/s12934-014-0173-5 · doi-reference
EspA is a novel fusion partner for expression of foreign proteins in Escherichia coli
10.1016/j.jbiotec.2010.09.940 · doi-reference
Clinical pharmacokinetics of the phosphate binder lanthanum carbonate
10.2165/00003088-200847090-00001 · doi-reference